Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06006728

Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy — NALIRI-PANC  

Pancreatic Adenocarcinoma Metastatic Clinical Trial

Official title:
Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy

Clinical Trial Summary

The objectives of the study are to evaluate the efficacy (primary endpoint: overall survival), safety (secondary endpoint) and the medico-economic impact (secondary endpoint) of nanoliposomal irinotecan combined with 5-fluorouracil and folinic acid in clinical practice

Clinical Trial Description

Nanoliposomal irinotecan combined with 5-fluorouracil and folinic acid was shown to be effective after gemcitabine-based treatment in patients with metastatic pancreatic adenocarcinoma in the phase III NAPOLI-1 randomized trial. Nanoliposomal irinotecan is authorized in combination with 5-fluorouracil (5-FU) and leucovorin (LV), as it has shown an improvement in overall survival (median +1.9 months, HR = 0.67) compared to 5-FU/LV alone, without degradation of quality-of-life scales. However, patients included in clinical trials regularly differ from patients in routine practice, and a real-life study is fundamental in this poor prognosis situation where quality of life preservation is paramount ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06006728
Study type Observational
Source University Hospital, Bordeaux
Contact
Status Completed
Phase
Start date October 6, 2023
Completion date October 31, 2023
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03213626 - Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma Phase 2
Recruiting NCT05077800 - FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer Phase 2
Completed NCT01715142 - Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer Early Phase 1
Completed NCT02179970 - To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers Phase 1
Completed NCT02195180 - Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma Phase 2
Recruiting NCT06051851 - Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer Phase 2
Recruiting NCT03633734 - Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma Phase 1/Phase 2
Completed NCT03529175 - Scheduling Nab-paclitaxel With Gemcitabine Phase 2
Recruiting NCT05360264 - tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr Phase 2
Recruiting NCT04150042 - SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells Phase 1
Withdrawn NCT03127124 - QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer Phase 1/Phase 2
Not yet recruiting NCT06076837 - The Seven Trial: Exploiting the Unfolded Protein Response Phase 1
Recruiting NCT06396637 - PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC Phase 2
Completed NCT01053013 - Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer Phase 2